<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30157398</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>379</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>Aug</Month><Day>30</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine.</ArticleTitle><Pagination><StartPage>834</StartPage><EndPage>845</EndPage><MedlinePgn>834-845</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1716677</ELocationID><Abstract><AbstractText Label="BACKGROUND">Mass campaigns with oral poliovirus vaccine (OPV) have brought the world close to the eradication of wild poliovirus. However, to complete eradication, OPV must itself be withdrawn to prevent outbreaks of vaccine-derived poliovirus (VDPV). Synchronized global withdrawal of OPV began with serotype 2 OPV (OPV2) in April 2016, which presented the first test of the feasibility of eradicating all polioviruses.</AbstractText><AbstractText Label="METHODS">We analyzed global surveillance data on the detection of serotype 2 Sabin vaccine (Sabin-2) poliovirus and serotype 2 vaccine-derived poliovirus (VDPV2, defined as vaccine strains that are at least 0.6% divergent from Sabin-2 poliovirus in the viral protein 1 genomic region) in stool samples from 495,035 children with acute flaccid paralysis in 118 countries and in 8528 sewage samples from four countries at high risk for transmission; the samples were collected from January 1, 2013, through July 11, 2018. We used Bayesian spatiotemporal smoothing and logistic regression to identify and map risk factors for persistent detection of Sabin-2 poliovirus and VDPV2.</AbstractText><AbstractText Label="RESULTS">The prevalence of Sabin-2 poliovirus in stool samples declined from 3.9% (95% confidence interval [CI], 3.5 to 4.3) at the time of OPV2 withdrawal to 0.2% (95% CI, 0.1 to 2.7) at 2 months after withdrawal, and the detection rate in sewage samples declined from 71.0% (95% CI, 61.0 to 80.0) to 13.0% (95% CI, 8.0 to 20.0) during the same period. However, 12 months after OPV2 withdrawal, Sabin-2 poliovirus continued to be detected in stool samples (&lt;0.1%; 95% CI, &lt;0.1 to 0.1) and sewage samples (8.0%; 95% CI, 5.0 to 13.0) because of the use of OPV2 in response to VDPV2 outbreaks. Nine outbreaks were reported after OPV2 withdrawal and were associated with low coverage of routine immunization (odds ratio, 1.64 [95% CI, 1.14 to 2.54] per 10% absolute decrease) and low levels of population immunity (odds ratio, 2.60 [95% CI, 1.35 to 5.59] per 10% absolute decrease) within affected countries.</AbstractText><AbstractText Label="CONCLUSIONS">High population immunity has facilitated the decline in the prevalence of Sabin-2 poliovirus after OPV2 withdrawal and restricted the circulation of VDPV2 to areas known to be at high risk for transmission. The prevention of VDPV2 outbreaks in these known areas before the accumulation of substantial cohorts of children susceptible to type 2 poliovirus remains a high priority. (Funded by the Bill and Melinda Gates Foundation and the World Health Organization.).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blake</LastName><ForeName>Isobel M</ForeName><Initials>IM</Initials><Identifier Source="ORCID">0000-0002-3977-1318</Identifier><AffiliationInfo><Affiliation>From the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pons-Salort</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molodecky</LastName><ForeName>Natalie A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diop</LastName><ForeName>Ousmane M</ForeName><Initials>OM</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chenoweth</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandyopadhyay</LastName><ForeName>Ananda S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaffran</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutter</LastName><ForeName>Roland W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassly</LastName><ForeName>Nicholas C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Disease Epidemiology, Imperial College London, London (I.M.B., M.P.-S., N.A.M., N.C.G.); the Polio Eradication Department, World Health Organization, Geneva (O.M.D., P.C., M.Z., R.W.S.); and the Bill and Melinda Gates Foundation, Seattle (A.S.B.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant><Grant><GrantID>MR/R015600/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012722">Sewage</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2018 Oct;24(10):1491. doi: 10.1038/s41591-018-0228-y</RefSource><PMID Version="1">30297892</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000349" MajorTopicYN="N">Africa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001208" MajorTopicYN="N">Asia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012722" MajorTopicYN="N">Sewage</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>8</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30157398</ArticleId><ArticleId IdType="pmc">PMC5985919</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1716677</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Famulare M, Chang S, Iber J, et al. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria. J Virol 2015;90:317-31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702576</ArticleId><ArticleId IdType="pubmed">26468545</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern A, Yeh MT, Zinger T, et al. The Evolutionary Pathway to Virulence of an RNA Virus. Cell 2017;169:35-46 e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5787669</ArticleId><ArticleId IdType="pubmed">28340348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005;59:587- 635.</Citation><ArticleIdList><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004;292:1696-701.</Citation><ArticleIdList><ArticleId IdType="pubmed">15479934</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease C, Prevention. Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep 2001;50:222-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11300627</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams A, Salisbury DM. Eradicating polio. Science 2015;350:609.</Citation><ArticleIdList><ArticleId IdType="pubmed">26542542</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulating vaccine-derived poliovirus. (Accessed 22 November, 2016, at http://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/.)</Citation></Reference><Reference><Citation>WHO. Meeting of the strategic advisory group of experts on immunization, November 2012 - conclusions and recommendations. Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations 2013;88:1-16.</Citation></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016. MMWR Morb Mortal Wkly Rep 2016;65:934-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>11th Meeting of the SAGE Polio working group. Conclusions and recommendations. 2016. (Accessed 7 November, 2017, at http://www.who.int/immunization/sage/meetings/2016/april/1_11th_Meeting_SAGE_Polio_Working _Group_January_2016.pdf?ua=1.)</Citation></Reference><Reference><Citation>Responding to a poliovirus event or outbreak part 2: Protocol for poliovirus type 2. 2017. (Accessed August, 2017, at http://polioeradication.org/wp-content/uploads/2017/05/POL-SOPs-Part- 2-260517-.pdf.)</Citation></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. The Journal of infectious diseases 2014;210 Suppl 1:S475-84.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316870</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita I, Nakane M, Fenner F. Public health. Is polio eradication realistic? Science 2006;312:852-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">16690846</ArticleId></ArticleIdList></Reference><Reference><Citation>Diop OM, Asghar H, Gavrilin E, et al. Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 - Worldwide, 2016-2017. MMWR Morb Mortal Wkly Rep 2017;66:538-42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657872</ArticleId><ArticleId IdType="pubmed">28542124</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroiss SJ, Famulare M, Lyons H, McCarthy KA, Mercer LD, Chabot-Couture G. Evaluating cessation of the type 2 oral polio vaccine by modeling pre- and post-cessation detection rates. Vaccine 2017;35:5674-81.</Citation><ArticleIdList><ArticleId IdType="pubmed">28890193</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitt A, Diop OM, Tangermann RH, et al. Surveillance systems to track progress toward global polio eradication - worldwide, 2012-2013. MMWR Morb Mortal Wkly Rep 2014;63:356-61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584778</ArticleId><ArticleId IdType="pubmed">24759658</ArticleId></ArticleIdList></Reference><Reference><Citation>Polio Laboratory manual. 2004. (Accessed September, 2017, at http://polioeradication.org/wp-content/uploads/2017/05/Polio_Lab_Manual04.pdf.)</Citation></Reference><Reference><Citation>S1 Supplement to the WHO polio laboratory manual (Accessed September, 2017, at http://polioeradication.org/wp-content/uploads/2017/05/NewAlgorithmForPoliovirusIsolationSupplement1.pdf.)</Citation></Reference><Reference><Citation>Grassly NC, Jafari H, Bahl S, et al. Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. The Journal of infectious diseases 2012;205:1554-61.</Citation><ArticleIdList><ArticleId IdType="pubmed">22448007</ArticleId></ArticleIdList></Reference><Reference><Citation>Classification and reporting of vaccine-derived polioviruses (VDPV) GPEI guidelines. 2016. (Accessed 31 October, 2017, at http://polioeradication.org/wp-content/uploads/2016/09/Reporting- and-Classification-of-VDPVs_Aug2016_EN.pdf.)</Citation></Reference><Reference><Citation>Asghar H, Diop OM, Weldegebriel G, et al. Environmental surveillance for polioviruses in the Global Polio Eradication Initiative. The Journal of infectious diseases 2014;210 Suppl 1:S294- 303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10578309</ArticleId><ArticleId IdType="pubmed">25316848</ArticleId></ArticleIdList></Reference><Reference><Citation>Polio Environmental Surveillance Expansion Plan. 2015. at http://polioeradication.org/wp- content/uploads/2016/07/GPLN_ExpansionPlanES.pdf.)</Citation></Reference><Reference><Citation>Guidelines on environmental surveillance for detection of polioviruses. 2015. (Accessed 04 October, 2016, at http://polioeradication.org/wp- content/uploads/2016/07/GPLN_GuidelinesES_April2015.pdf.)</Citation></Reference><Reference><Citation>Rue H, Martino S, Lindgren F, Simpson D, Riebler A, T. KE. INLA: Functions which allow to perform full Bayesian analysis of latent Gaussian models using Integrated Nested Laplace Approximation. R package version 0.0-1403203700. 2014.</Citation></Reference><Reference><Citation>R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria http://www.R-project.org/. 2014.</Citation></Reference><Reference><Citation>Pons-Salort M, Molodecky NA, O'Reilly KM, et al. Population immunity against serotype-2 poliomyelitis leading up to the global withdrawal of the oral poliovirus vaccine: Spatio-temporal modelling of surveillance data. PLoS medicine 2016;13:e1002140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5049753</ArticleId><ArticleId IdType="pubmed">27701425</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S. Asymptomatic equivalence of Bayes cross validation and widely applicable information criterion in sinhular learning theory. Jounral of Machine Learning Research 2010;11:3571 - 94.</Citation></Reference><Reference><Citation>Jorba J, Diop OM, Iber J, et al. Update on Vaccine-Derived Polioviruses - Worldwide, January 2016-June 2017. MMWR Morb Mortal Wkly Rep 2017;66:1185-91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5689216</ArticleId><ArticleId IdType="pubmed">29095803</ArticleId></ArticleIdList></Reference><Reference><Citation>Modeled Surfaces. ICF International. (Accessed 26 October, 2017, at http://spatialdata.dhsprogram.com.)</Citation></Reference><Reference><Citation>Worldpop. 2017. (Accessed 30 October, 2017, at www.worldpop.org.uk.)</Citation></Reference><Reference><Citation>Etsano A, Damisa E, Shuaib F, et al. Environmental Isolation of Circulating Vaccine-Derived Poliovirus After Interruption of Wild Poliovirus Transmission - Nigeria, 2016. MMWR Morb Mortal Wkly Rep 2016;65:770-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">27490081</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Platt L, Mach O, Jafari H, Aylward RB. The new polio eradication end game: rationale and supporting evidence. The Journal of infectious diseases 2014;210 Suppl 1:S434-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316865</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang QS, Greening G, Baker MG, et al. Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet 2005;366:394-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054940</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Salort M, Burns CC, Lyons H, et al. Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame. PLoS Pathog 2016;12:e1005728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4934862</ArticleId><ArticleId IdType="pubmed">27384947</ArticleId></ArticleIdList></Reference><Reference><Citation>Responding to a poliovirus event and outbreak. Part 2: Protocol for poliovirus type 2, Amended version, May 1, 2017. 2017. (Accessed 27 October, 2017, at http://polioeradication.org/wp- content/uploads/2017/05/POL-SOPs-Part-2-260517-.pdf.).</Citation></Reference><Reference><Citation>McCarthy KA, Chabot-Couture G, Famulare M, Lyons HM, Mercer LD. The risk of type 2 oral polio vaccine use in post-cessation outbreak response. BMC Med 2017;15:175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5627419</ArticleId><ArticleId IdType="pubmed">28974220</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake IM, Chenoweth P, Okayasu H, Donnelly CA, Aylward RB, Grassly NC. Faster Detection of Poliomyelitis Outbreaks to Support Polio Eradication. Emerging infectious diseases 2016;22:449-56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766913</ArticleId><ArticleId IdType="pubmed">26890053</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>